biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
AXIM Biotechnologies projects
5 ClinicalTrials.gov programs sponsored by AXIM Biotechnologies.
AXIM Biotechnologies has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Chewing Gum
AXIM BIOTECHNOLOGIES, INC.
THC
1 trial -
ONC206 Powder
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
1 trial -
SP_MH20VYX
AXIM BIOTECHNOLOGIES, INC.
AML
1 trial -
WT1-loaded CBDC Vaccine
AXIM BIOTECHNOLOGIES, INC.
AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow
1 trial -
Ziftomenib for Acute Myeloid Leukemia, Mixed P…
AXIM BIOTECHNOLOGIES, INC.
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia
1 trial
Frequently asked questions
How many clinical projects does AXIM Biotechnologies have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.